Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ying Huang"'
Publikováno v:
Int J Biostat
In randomized clinical trials, researchers are often interested in identifying an inexpensive intermediate study endpoint (typically a biomarker) that is a strong effect modifier of the treatment effect on a longer-term clinical endpoint of interest.
Autor:
Ying Huang, Peter B. Gilbert
Publikováno v:
Epidemiologic Methods. 5:93-112
We develop a transport formula for predicting overall cumulative vaccine efficacy through time t ( V E ( t ) $$VE(t)$$ ) to prevent clinically significant infection with a genetically diverse pathogen (e. g., HIV infection) in a new setting for which
SAA1 genetic polymorphisms are associated with plasma glucose concentration in non-diabetic subjects
Autor:
Xiang Xie, Xiao-Mei Li, Fen Liu, Bang-Dang Chen, Ying-Ying Zheng, Xiang Ma, Zhen-Yan Fu, Yi-Tong Ma, Ying Huang, Yi-Ning Yang
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 51:2331-2334
Background: Serum amyloid A (SAA) was reported to be associated with insulin resistance and type-2 diabetes. The present study aimed to investigate the association of SAA genetic polymorphisms with plasma glucose levels in non-diabetic subjects. Meth
Autor:
Susan Buchbinder, Ying Huang, Douglas I. Grove, Peter B. Gilbert, Glenda Gray, Scott M. Hammer, Steven G. Self, Lawrence Corey, Erin E. Gabriel, James G. Kublin
Publikováno v:
Statistical Communications in Infectious Diseases. 3
Five preventative HIV vaccine efficacy trials have been conducted over the last 12 years, all of which evaluated vaccine efficacy (VE) to prevent HIV infection for a single vaccine regimen versus placebo. Now that one of these trials has supported pa